Publications en collaboration avec des chercheurs de Universitat de Barcelona (26)

2024

  1. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

    eClinicalMedicine, Vol. 71

2023

  1. Genomic landscape of follicular lymphoma across a wide spectrum of clinical behaviors

    Hematological Oncology, Vol. 41, Núm. 4, pp. 631-643

  2. Impact of the COVID-19 pandemic on the diagnosis and treatment of onco-hematologic patients: a discussion paper

    Revista Espanola de Quimioterapia, Vol. 36, Núm. 1, pp. 1-25

  3. Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia

    Seminars in Hematology

  4. Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis

    Seminars in Hematology

2022

  1. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

    Blood cancer journal, Vol. 12, Núm. 4, pp. 68

  2. Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients

    Annals of Hematology, Vol. 101, Núm. 9, pp. 2053-2067

  3. Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19

    Blood Advances

  4. Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 11, pp. 1196-1205

  5. NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial

    Cancers, Vol. 14, Núm. 20

  6. Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report

    American Journal of Hematology

  7. Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients

    Leukemia and Lymphoma, Vol. 63, Núm. 3, pp. 538-550

2021

  1. Genetically determined telomere length and multiple myeloma risk and outcome

    Blood Cancer Journal, Vol. 11, Núm. 4

2019

  1. Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma

    Leukemia

  2. Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study

    Leukemia and Lymphoma, Vol. 60, Núm. 7, pp. 1803-1811

2018

  1. Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing

    Haematologica

2017

  1. Identification of miRSNPs associated with the risk of multiple myeloma

    International Journal of Cancer, Vol. 140, Núm. 3, pp. 526-534

2015

  1. Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length

    International Journal of Cancer, Vol. 136, Núm. 5, pp. E351-E358

  2. Type 2 diabetes-related variantsinfluence the risk of developing multiple myeloma: Results from the IMMEnSE consortium

    Endocrine-Related Cancer, Vol. 22, Núm. 4, pp. 545-559

2014

  1. Genetic variants and multiple myeloma risk: IMMEnSE validation of the best reported associations - An extensive replication of the associations from the candidate gene era

    Cancer Epidemiology Biomarkers and Prevention, Vol. 23, Núm. 4, pp. 670-674